These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11399024)

  • 1. In vitro development of resistance to newer fluoroquinolones in Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin.
    Mayer S; Boos M; Köhrer K; Fluit AC; Schmitz FJ
    Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):288-91. PubMed ID: 11399024
    [No Abstract]   [Full Text] [Related]  

  • 2. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
    Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.
    Pestova E; Beyer R; Cianciotto NP; Noskin GA; Peterson LR
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2000-4. PubMed ID: 10428926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
    Morrissey I; George J
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae.
    Richardson DC; Bast D; McGeer A; Low DE
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1911-4. PubMed ID: 11353652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Coyle EA; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1654-9. PubMed ID: 11353608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary targets of fluoroquinolones in Streptococcus pneumoniae.
    Fukuda H; Hiramatsu K
    Antimicrob Agents Chemother; 1999 Feb; 43(2):410-2. PubMed ID: 9925547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.
    Gould KA; Pan XS; Kerns RJ; Fisher LM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2108-15. PubMed ID: 15155208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.
    Millichap JJ; Pestova E; Siddiqui F; Noskin GA; Peterson LR
    J Clin Microbiol; 2001 Jul; 39(7):2719-21. PubMed ID: 11427605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae.
    Onodera Y; Uchida Y; Tanaka M; Sato K
    J Antimicrob Chemother; 1999 Oct; 44(4):533-6. PubMed ID: 10588315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.
    Pestova E; Millichap JJ; Noskin GA; Peterson LR
    J Antimicrob Chemother; 2000 May; 45(5):583-90. PubMed ID: 10797078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
    Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
    J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.
    Bast DJ; Low DE; Duncan CL; Kilburn L; Mandell LA; Davidson RJ; de Azavedo JC
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3049-54. PubMed ID: 11036021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
    Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
    Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms and spread of fluoroquinolone resistance in Streptococcus pneumoniae.
    Varon E; Gutmann L
    Res Microbiol; 2000; 151(6):471-3. PubMed ID: 10961461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.